Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Blood (2023) 141 (14): 1685–1690.

https://doi.org/10.1182/blood.2022017789

Published: 2023

Includes: Supplemental data

Journal Articles

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Thomas Moehler, MD PhD, Magdalena Ruiz, MD MSc, Vicky Casey, Luana Margotto Soares, Fil Manuguid, Kriti Jindal, MS, Sari Heitner Enschede, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-135921

Published: 2020

Journal Articles

Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling.

Blood (2007) 110 (11): 2484.

https://doi.org/10.1182/blood.V110.11.2484.2484

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

Karène Mahtouk, Dirk Hose, Pierre Raynaud, Michael Hundemer, Michel Jourdan, Eric Jourdan, Veronique Pantesco, Marion Baudard, John De Vos, Marion Larroque, Thomas Moehler, Jean-Francois Rossi, Thierry Rème, Hartmut Goldschmidt, Bernard Klein

Blood (2007) 109 (11): 4914–4923.

https://doi.org/10.1182/blood-2006-08-043232

Published: 2007

Journal Articles

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Vaccination Strategies Determined by Microarray Analysis.

Maud Condomines, PharmD, Dirk Hose, MD, PhD, Thierry Reme, PhD, Michael Hundemer, John De Vos, MD, PhD, Marion Baudard, MD, PhD, Thomas Moehler, Veronique Pantesco, Jean-Francois Schved, MD, PhD, Jean-Francois Rossi, MD, PhD, Hartmut Goldschmidt, MD, PhD, Bernard Klein, PhD

Blood (2006) 108 (11): 3401.

https://doi.org/10.1182/blood.V108.11.3401.3401

Published: 2006

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Heparanase Influences Expression and Shedding of Syndecan-1, and Its Expression by the Bone Marrow Environment Is a Bad Prognostic Factor in Multiple Myeloma.

Karene Mahtouk, Dirk Hose, Thierry Reme, Michael Hundemer, Michel Jourdan, Eric Jourdan, Veronique Pantesco, Marion Baudard, John De Vos, Marion Larroque, Thomas Moehler, Jean-Francois Rossi, Hartmut Goldschmidt, Bernard Klein

Blood (2006) 108 (11): 3502.

https://doi.org/10.1182/blood.V108.11.3502.3502

Published: 2006

Journal Articles

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Ute Hegenbart, MD, Stefan O. Schonland, MD, Thomas Moehler, MD, Axel Benner, PhD, Sabine Gerull, MD, Martin Goerner, MD, Hans-Joerg Schaefer, MD, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2006) 108 (11): 3018.

https://doi.org/10.1182/blood.V108.11.3018.3018

Published: 2006

Journal Articles

Impact of Whole-Body Magnetic Resonance Imaging on Staging in Patients with Newly Diagnosed Plasma Cell Disease.

Martin Zoz, Andreas Baldauf, Anne Schipp, Jens Hillengass, Anthony D. Ho, Harmut Goldschmidt, Jochen Hansmann, Thomas Moehler

Blood (2006) 108 (11): 5061.

https://doi.org/10.1182/blood.V108.11.5061.5061

Published: 2006

Journal Articles

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Jens Hillengass, MD, Christian Zechmann, MD, Andreas Nadler, Stefan Delorme, MD, Axel Benner, Christiane Heiss, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Thomas Moehler, MD

Blood (2006) 108 (11): 5079.

https://doi.org/10.1182/blood.V108.11.5079.5079

Published: 2006

Journal Articles

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Jens Hillengass, MD, Klaus Wasser, MD, Axel Benner, Stefan Delorme, MD, Christian Zechmann, MD, Anthony D. Ho, Hartmut Goldschmidt, Thomas Moehler, MD

Blood (2005) 106 (11): 5062.

https://doi.org/10.1182/blood.V106.11.5062.5062

Published: 2005

Journal Articles

Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.

Sabine Gerull, MD, Ute Hegenbart, MD, Martin Goerner, MD, Axel Benner, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Anthony D. Ho, MD

Blood (2004) 104 (11): 2759.

https://doi.org/10.1182/blood.V104.11.2759.2759

Published: 2004

Journal Articles

High CD34+ Cell Dose Is a Significant Factor for Hematologic Reconstitution of Patients with Multiple Myeloma (MM) or AL-Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

Jens Klaus, Doris Herrmann, Ute Hegenbart, Gerlinde Egerer, Friedrich W. Cremer, Iris Breitkreutz, Axel Benner, Stefan Fruehauf, Thomas Moehler, Anthony D. Ho, Hartmut Goldschmidt

Blood (2004) 104 (11): 1157.

https://doi.org/10.1182/blood.V104.11.1157.1157

Published: 2004

Journal Articles

Recovery of Polyclonal Immunoglobulin Synthesis after Autologous Stem Cell Transplantation in Multiple Myeloma Patients as a Prognostic Factor for Event-Free Survival.

Annette Höfer, Axel Benner, Jens Klaus, Iris Breitkreutz, Doris Herrmann, Friedrich W. Cremer, Sabine Gerull, Thomas Moehler, Gerlinde Egerer, Ute Hegenbart, Anthony D. Ho, Hartmut Goldschmidt

Blood (2004) 104 (11): 939.

https://doi.org/10.1182/blood.V104.11.939.939

Published: 2004

NARROW

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Vaccination Strategies Determined by Microarray Analysis.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Heparanase Influences Expression and Shedding of Syndecan-1, and Its Expression by the Bone Marrow Environment Is a Bad Prognostic Factor in Multiple Myeloma.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Impact of Whole-Body Magnetic Resonance Imaging on Staging in Patients with Newly Diagnosed Plasma Cell Disease.

Dynamic Contrast-Enhanced MRI Identifies a Distinct Group of Asymptomatic Myeloma Patients with Increased Bone Marrow Microcirculation.

Bone Marrow Microcirculation Parameter Amplitude A of Contrast-Enhanced Dynamic MRI Is a Prognostic Factor for Progressive Multiple Myeloma for Patients with Low Beta2-Microglobulin.

Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.

High CD34+ Cell Dose Is a Significant Factor for Hematologic Reconstitution of Patients with Multiple Myeloma (MM) or AL-Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

Recovery of Polyclonal Immunoglobulin Synthesis after Autologous Stem Cell Transplantation in Multiple Myeloma Patients as a Prognostic Factor for Event-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only